Galera Therapeutics Total Debt vs. Cash Per Share
GRTXDelisted Stock | USD 2.58 0.19 6.86% |
For Galera Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Galera Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Galera Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Galera Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Galera Therapeutics over time as well as its relative position and ranking within its peers.
Galera |
Galera Therapeutics Cash Per Share vs. Total Debt Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Galera Therapeutics's current stock value. Our valuation model uses many indicators to compare Galera Therapeutics value to that of its competitors to determine the firm's financial worth. Galera Therapeutics is rated as one of the top companies in total debt category among its peers. It is rated below average in cash per share category among its peers . The ratio of Total Debt to Cash Per Share for Galera Therapeutics is about 78,504,639 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Galera Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Galera Therapeutics' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Galera Total Debt vs. Competition
Galera Therapeutics is rated as one of the top companies in total debt category among its peers. Total debt of Health Care industry is currently estimated at about 327.27 Million. Galera Therapeutics totals roughly 152.3 Million in total debt claiming about 47% of equities under Health Care industry.
Galera Cash Per Share vs. Total Debt
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Galera Therapeutics |
| = | 152.3 M |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Galera Therapeutics |
| = | 1.94 X |
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
Galera Cash Per Share Comparison
Galera Therapeutics is currently under evaluation in cash per share category among its peers.
Galera Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Galera Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Galera Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Galera Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Galera Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania. Galera Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 30 people.
Galera Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Galera Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Galera Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Galera Therapeutics' important profitability drivers and their relationship over time.
Use Galera Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Galera Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Galera Therapeutics will appreciate offsetting losses from the drop in the long position's value.Galera Therapeutics Pair Trading
Galera Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Galera Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Galera Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Galera Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Galera Therapeutics to buy it.
The correlation of Galera Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Galera Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Galera Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Galera Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Galera Therapeutics position
In addition to having Galera Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Momentum Thematic Idea Now
Momentum
Large corporations operating in software, education, financial and car manufacturing industries. The Momentum theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Momentum Theme or any other thematic opportunities.
View All Next | Launch |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Other Consideration for investing in Galera Pink Sheet
If you are still planning to invest in Galera Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Galera Therapeutics' history and understand the potential risks before investing.
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |